title: Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab.
abstract: Most patients with primary central nervous system (CNS) lymphoma or systemic non-Hodgkin's lymphoma (NHL) involving the CNS relapse after an initial response to treatment, often presenting with leptomeningeal disease. Since the majority of these lymphomas are B-cell neoplasms expressing the CD20 surface antigen treatment with the chimeric monoclonal antibody (Mab) rituximab might be a new therapeutic option. Here, we report on 6 patients with relapsed CNS B-cell lymphoma who were treated with intraventricular or intrathecal applications of rituximab. One of these cases has already been reported.
authors.forename: Holger
authors.initials: H
authors.lastname: Schulz
authors.forename: Hendrik
authors.initials: H
authors.lastname: Pels
authors.forename: Ingo
authors.initials: I
authors.lastname: Schmidt-Wolf
authors.forename: Ulrich
authors.initials: U
authors.lastname: Zeelen
authors.forename: Ulrich
authors.initials: U
authors.lastname: Germing
authors.forename: Andreas
authors.initials: A
authors.lastname: Engert
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D006801:Humans; D007276:Injections, Intraventricular; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008577:Meningeal Neoplasms / Q000188:drug therapy; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab